Annexin A2 (AnxA2) is a calcium-dependent phospholipid-binding protein belonging to the annexin superfamily, involved in diverse cellular processes including membrane organization, exocytosis, endocytosis, and cytoskeletal dynamics. It forms a heterotetrameric complex with S100A10 (p11), which facilitates interactions with actin, phospholipids, and other proteins to regulate cell adhesion, migration, and membrane repair. AnxA2 is implicated in pathological conditions such as cancer metastasis, thrombosis, and autoimmune diseases due to its roles in fibrinolysis, angiogenesis, and extracellular matrix remodeling.
Antibodies targeting Annexin A2 are essential tools for studying its expression, localization, and function. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Monoclonal antibodies (e.g., clone 5) offer high specificity for detecting AnxA2 in human or murine samples, while polyclonal antibodies may detect conserved epitopes across species. Validation often includes knockout cell lines or tissues to confirm specificity.
In research, AnxA2 antibodies help elucidate its dual roles in health and disease. For example, elevated AnxA2 expression in tumors correlates with metastatic potential, while autoantibodies against AnxA2 are linked to antiphospholipid syndrome. However, cross-reactivity with other annexins (e.g., AnxA1. AnxA5) requires careful antibody selection. Overall, AnxA2 antibodies remain critical for exploring its therapeutic potential and biomarker utility in cancer, cardiovascular disorders, and immune dysregulation.